Journey Medical Touts Positive PK Data For Bacterial Infection Candidate

  • Journey Medical Corporation DERM announced PK comparability data of DFD-29 and key updates on the progress of its pivotal, Phase 3 study of DFD-29 for papulopustular rosacea in collaboration with Dr. Reddy's Laboratories Ltd RDY.
  • Papulopustular rosacea is associated with "whitehead" pustules, pus-filled blemishes, and red, swollen bumps. 
  • The PK study was designed as a comparative bioavailability study of DFD-29 (Minocycline Modified Release Capsules 40 mg) versus Solodyn (Minocycline Modified Release Tablets 105 mg). 
  • Minocycline is a prescription medicine used to treat the symptoms of many different bacterial infections.
  • A total of 24 healthy adult volunteers were enrolled and examined for up to 30 days. 
  • The study successfully demonstrated that the systemic exposure of DFD-29 (40 mg) was significantly lower than that of SOLODYN (105 mg). 
  • Additionally, the study showed that food did not significantly affect the pharmacokinetics of DFD-29.
  • Claude Maraoui, Co-Founder, President & CEO of Journey Medical, stated, "the PK data indicate the safety of DFD-29 is on par with Solodyn. 
  • The company looks forward to providing further updates on the DFD-29 program, including potential topline data from the Phase 3 studies anticipated in the first half of 2023.
  • Journey Medical also plans to file a New Drug Application in the second half of 2023. 
  • Price Action: DERM shares are down 9.23% at $1.18 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!